Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Cancer
Interventions: DRUG: I-131-CLR1404
Sponsor: Cellectar Biosciences, Inc.